Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M93,592Revenue $M6,494Net Margin (%)21.8Z-Score7.2
Enterprise Value $M93,569EPS $1.7Operating Margin %28.5F-Score7
P/E(ttm))61.4Cash Flow Per Share $4.4Pre-tax Margin (%)25.0Higher ROA y-yN
Price/Book16.310-y EBITDA Growth Rate %0Quick Ratio6.1Cash flow > EarningsY
Price/Sales13.45-y EBITDA Growth Rate %22.2Current Ratio6.3Lower Leverage y-yN
Price/Cash Flow17.9y-y EBITDA Growth Rate %11.0ROA % (ttm)11.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)30.1Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M799ROI % (ttm)17.8Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGJohn Hussman 2014-09-30 Buy 0.2%$83.13 - $96.21
($90.29)
$ 117.1830%New holding, 25000 sh.25,000
CELGKen Fisher 2014-09-30 Add0.02%$83.13 - $96.21
($90.29)
$ 117.1830%Add 77.12%232,137
CELGGeorge Soros 2014-09-30 Sold Out -0.45%$83.13 - $96.21
($90.29)
$ 117.1830%Sold Out0
CELGJoel Greenblatt 2014-09-30 Sold Out -0.07%$83.13 - $96.21
($90.29)
$ 117.1830%Sold Out0
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 117.1854%New holding, 688000 sh.688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 117.1854%New holding, 63980 sh.63,980
CELGKen Fisher 2014-06-30 Add0.01%$68.45 - $86.8
($75.89)
$ 117.1854%Add 75.59%131,064
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 117.1854%Reduce -51.74%144,140
CELGRay Dalio 2014-06-30 Sold Out -0.08%$68.45 - $86.8
($75.89)
$ 117.1854%Sold Out0
CELGJohn Burbank 2014-06-30 Sold Out -0.01%$68.45 - $86.8
($75.89)
$ 117.1854%Sold Out0
CELGRay Dalio 2014-03-31 Add0.07%$69.65 - $85.97
($79.51)
$ 117.1847%Add 962.69%142,400
CELGJohn Burbank 2014-03-31 Buy 0.01%$69.65 - $85.97
($79.51)
$ 117.1847%New holding, 1670 sh.3,340
CELGKen Fisher 2014-03-31 Add0.01%$69.65 - $85.97
($79.48)
$ 117.1847%Add 1591.8%74,642
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.51)
$ 117.1847%Sold Out0
CELGRonald Muhlenkamp 2013-12-31 Add0.12%$72.25 - $85.39
($79.05)
$ 117.1848%Add 2.87%294,850
CELGRay Dalio 2013-12-31 Buy 0.01%$72.25 - $85.39
($79.05)
$ 117.1848%New holding, 6700 sh.13,400
CELGJohn Keeley 2013-09-30 Buy $60.13 - $77.31
($70.14)
$ 117.1867%New holding, 1320 sh.2,640
CELGMario Gabelli 2013-09-30 Add$60.13 - $77.31
($70.14)
$ 117.1867%Add 29.5%20,940
CELGKen Fisher 2013-09-30 Reduce$60.13 - $77.31
($70.14)
$ 117.1867%Reduce -44.85%4,980
CELGJohn Hussman 2013-09-30 Sold Out -0.31%$60.13 - $77.31
($70.14)
$ 117.1867%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CELG John Hussman 2014-09-3025,00000.2New Buy
CELG Ken Fisher 2014-09-30232,1370.030.05+77.12%
CELG Mario Gabelli 2014-09-3025,76000.01+11.42%
CELG Ronald Muhlenkamp 2014-09-30146,9400.022.5+1.94%
CELG George Soros 2014-09-30000Sold Out
CELG Joel Greenblatt 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Daniel Thomas Osee remarks 2014-12-15Sell30,000$115.061.84view
KAPLAN GILLADirector 2014-12-08Sell15,000$118.2-0.86view
Daniel Thomas Osee remarks 2014-11-24Sell33,818$110.276.27view
KARSEN PERRY Asee remarks 2014-11-12Sell39,420$107.239.28view
HUGIN ROBERT Jsee remarks 2014-11-03Sell158,000$106.689.84view
MARIO ERNESTDirector 2014-10-27Sell100,000$102.8513.93view
CASEY MICHAEL DDirector 2014-10-24Sell15,000$102.9413.83view
KAPLAN GILLADirector 2014-09-08Sell30,000$93.7325.02view
LOUGHLIN JAMES JDirector 2014-08-22Sell20,000$91.2528.42view
CASEY MICHAEL DDirector 2014-08-14Sell30,000$88.5932.27view

Press Releases about CELG :

    Quarterly/Annual Reports about CELG:

    News about CELG:

    Articles On GuruFocus.com
    UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
    Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
    Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
    Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 
    Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
    David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Trying to Beat the Market Is a Fool’s Errand Oct 17 2013 
    Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
    comment on CELG Mar 20 2013 


    More From Other Websites
    Celgene: European Decision Not Best Case Scenario, Not Worst Case Either Dec 19 2014
    Juno Shares Exploded Post-IPO. Should You Consider Buying Them? Dec 19 2014
    Cramer's Mad Dash: Tale of two biotechs Dec 19 2014
    European Panel Gives Positive Opinion on Celgene Cancer Drug Dec 19 2014
    8:12 am Celgene confirms EMA CHMP adopted a positive opinion for continuous oral treatment with... Dec 19 2014
    Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in... Dec 19 2014
    Biotech: More Upside in 2015? Dec 18 2014
    Cramer: Here's what the Fed did today Dec 17 2014
    Data Presented on REVLIMID® (lenalidomide) Compared with Investigators' Choice in... Dec 16 2014
    Results from Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plus Low-Dose dexamethasone in... Dec 16 2014
    Meet 5 Top Biotech Stocks Holding Up In Shaky Market Dec 13 2014
    IBD 50: Growth Stocks Fight The Fight In Weak Tape Dec 12 2014
    Celgene's Abraxane Succeeds In Early Breast Cancer Dec 11 2014
    Cramer: Celgene has phenomenal pipeline Dec 10 2014
    Trading Biotechs From His Bedroom Nate Pile Beats The Street Dec 10 2014
    Celgene Up on Positive Revlimid Data Presented at ASH Dec 09 2014
    Bluebird Bio Stock Spikes On New Blood Treatment Dec 09 2014
    Combination of ISTODAX® (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of... Dec 09 2014
    Cramer: Here's why we're selling off Dec 09 2014
    Cramer's Mad Dash: BLUE big winner Dec 09 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK